In this study, there was evaluation of pregnancy per AI (P/AI) as a result of the first postpartum AI following four ovulation-synchronization treatments. Treatment regimens were Ovsynch-56 (OVS, n = 875; GnRH1-7d-PGF-56h-GnRH2-16h-FTAI), CIDR-OVS (n = 1001; OVS plus CIDR inserts between GnRH1 and PGF), Double-Ovsynch (DOVS, n = 663; imposing Pre-OVS followed by breeding-OVS 7 days later), and Modified-DOVS (M-DOVS, n = 1397; imposing Pre-OVS followed either by breeding-OVS or CIDR-OVS based upon the ovarian structure at GnRH1). Cows with a corpus luteum were assigned to a breeding-OVS treatment regimen and those that did not have a corpus luteum were assigned to the CIDR-OVS treatment regimen. Compared with OVS, the P/AI of the cows in the M-DOVS (OR = 1.5, P = 0.001) and CIDR-OVS (OR = 1.4, P = 0.017) was greater at day 30. At day 70, only in the M-DOVS group was there a greater P/AI compared with the OVS group (OR = 1.7, P < 0.001). Pregnancy loss between days 30 and 70 was greater in cows of the CIDR-OVS (OR = 1.9, P = 0.014) compared with those of the OVS group. In cows of the M-DOVS, the dominant ovarian structures (follicle, corpus luteum or cyst) at different time-points of the pre-synchronization period and occurrence of estrus at the end of this period were not associated with P/AI at day 30 post-AI. In conclusion, imposing CIDR-OVS in cows that did not respond to pre-synchronization treatments, resulted in an enhanced pregnancy percentage with the use of the DOVS.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anireprosci.2020.106356DOI Listing

Publication Analysis

Top Keywords

treatment regimen
12
corpus luteum
12
compared ovs
12
respond pre-synchronization
8
pre-synchronization treatments
8
pregnancy percentage
8
imposing pre-ovs
8
pre-ovs breeding-ovs
8
luteum assigned
8
cows m-dovs
8

Similar Publications

Importance: Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, a high incidence in non-Hispanic Black women, and a high risk of progression to metastatic cancer, a devastating sequela with a 12- to 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative breast cancer was chemotherapy after surgery. However, it was not known whether the addition of immune therapy to postsurgery chemotherapy would be beneficial.

View Article and Find Full Text PDF

Unlabelled: Current guidelines recommend 6-h milk fasting in periprocedural settings; however, recent evidence suggests potential overconservativeness and supports more liberal pediatric fasting protocols. This study assessed the gastric emptying of two different milk quantities in elementary school-age children using gastric ultrasonography. This prospective crossover trial involved 30 healthy children who fasted overnight on two separate occasions within one month, consuming either 5 or 10 mL/kg of milk.

View Article and Find Full Text PDF

Objectives: The objectives were to determine intensive care unit (ICU) incidence of broncho-aspiration (BA) and the effect of monitoring BA prevention protocols.

Methods: The Health Network Warehouse was interrogated for the diagnosis of BA in patients older than 18 years in the surgical ICU (SICU) from January 2010 to December 2020. A BA prevention bundle protocol was prospectively monitored during all consecutive SICU admissions from August 2021 to November 2021 until discharge/death (n = 159).

View Article and Find Full Text PDF

Impaired insulin secretion contributes to the pathogenesis of type 1 diabetes mellitus through autoimmune destruction of pancreatic β-cells and the pathogenesis of severe forms of type 2 diabetes mellitus through β-cell dedifferentiation and other mechanisms. Replenishment of malfunctioning β-cells via islet transplantation has the potential to induce long-term glycemic control in the body. However, this treatment option cannot widely be implemented in clinical due to healthy islet donor shortage.

View Article and Find Full Text PDF

Background: Radio-chemotherapy remains the mainstay of glioblastoma first-line treatment after extended surgery, but the prognosis is still poor. PARP inhibitors like olaparib may improve glioblastoma outcomes. We implemented a phase 1-2a trial to assess the safety and efficacy of olaparib combined with standard radio-chemotherapy as a first-line treatment in unresected glioblastoma patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!